Paul W. Hruz, MD, PhD
Our research efforts are directed toward understanding facilitative glucose transport as it relates to normal and disordered glucose homeostasis. A primary effort in our laboratory is the determination of structure/function relationships within the facilitative glucose transport proteins (GLUTs). We are using state of the art chemical and biophysical approaches to the determination of tertiary and quaternary structures of the human erythrocyte glucose transporter GLUT1 and the insulin responsive glucose transporter GLUT4.
In addition, we are also investigating the in vitro and in vivo effects of HIV protease inhibitors (PIs)on GLUT function. The goal of this research is to identify the molecular mechanisms that lead HIV infected patients receiving PIs to develop insulin resistance.
Stephen I. Stone, MD
The goal of the Stone lab is to promote concepts of precision medicine, technology, and design to the care of individuals suffering from complex endocrine conditions including diabetes, insulin resistance, and obesity. By studying unique individuals, we hope to gain insights into the underlying mechanisms of disease. We hope to translate this information into new treatments for diabetes, obesity, and insulin resistance.
Michael D. Thompson, MD, PhD
Our lab focuses on understanding factors that are involved in disease progression in non-alcoholic fatty liver disease (NAFLD). Our studies are based on the developmental origins hypothesis of adult disease which states that in utero and perinatal events drive risk for chronic disease. We are particularly interested in the effects of parental overnutrition on the offspring.
Arpita K. Vyas, MD, DCH
The central research goal of our lab is to identify the molecular underpinnings of adverse maternal fetal cardio-metabolic outcomes from exposure to altered sex hormone milieu and endocrine disrupting chemicals in-utero.